Shareholder Votes

DIVERSIFIED HEALTHCARE TRUST shareholders approved Advisory vote on executive compensation (Say-on-Pay) at the 2026-06-10 meeting.

“The Company’s shareholders also voted on a non-binding advisory resolution on the compensation paid to the Company’s named executive officers as disclosed pursuant to Item 402 of Regulation S-K in the 2026 Proxy Statement. This proposal received the following votes: For Against Abstain Broker Non-Votes 176,612,032 8,812,215 245,865 17,192,383”

DIVERSIFIED HEALTHCARE TRUST shareholders approved Election of seven Trustees to the Board of Trustees for one-year terms at the 2026-06-10 meeting.

“The following persons were elected as Trustees and received the following votes: Nominee Votes For Withhold Broker Non-Votes Christopher J. Bilotto 181,906,682 3,763,430 17,192,383 Alan Felder 182,044,604 3,625,508 17,192,383 Lisa Harris Jones 160,305,823 25,364,289 17,192,383 Phyllis M. Hollis 181,544,266 4,125,846 17,192,383 Dawn K. Neher 176,872,256 8,797,856 17,192,383 Adam Portnoy 144,455,435 41,214,677 17,192,383 Jeffrey P. Somers 146,947,873 38,722,239 17,192,383”

LENZ Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-12 meeting.

“Votes For Votes Against Abstentions Broker Non-Votes 24,310,915 55,181 75,972 —”

LENZ Therapeutics, Inc. shareholders approved Election of Class II Directors at the 2026-06-12 meeting.

“Nominee Votes For Votes Withheld Broker Non-Votes Evert Schimmelpennink 20,216,637 230,219 3,995,212 Jeff George 13,462,359 6,984,497 3,995,212 Shelley Thunen 20,215,686 231,170 3,995,212”

Service Properties Trust shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company's independent auditors for the 2026 fiscal year. at the 2026-06-11 meeting.

“The Company’s shareholders also ratified the appointment of Deloitte & Touche LLP as the Company’s independent auditors to serve for the 2026 fiscal year. This proposal received the following votes: For Against Abstain Broker Non-Votes 117,966,231 8,958,631 179,710 N/A”

Service Properties Trust shareholders approved Non-binding advisory resolution on the compensation paid to the Company's named executive officers. at the 2026-06-11 meeting.

“The Company’s shareholders also voted on a non-binding advisory resolution on the compensation paid to the Company’s named executive officers as disclosed pursuant to Item 402 of Regulation S-K in the 2026 Proxy Statement. This proposal received the following votes: For Against Abstain Broker Non-Votes 93,864,625 18,402,279 659,098 14,178,570”

Service Properties Trust shareholders approved Election of seven Trustees to the Company's Board of Trustees for a one-year term. at the 2026-06-11 meeting.

“At the Annual Meeting, the Company’s shareholders voted on the election of seven Trustees to the Company’s Board of Trustees each for a one year term of office continuing until the Company’s 2027 annual meeting of shareholders and until her or his respective successor is duly elected and qualifies. The following persons were elected as Trustees and received the following votes: Nominee Votes For Against Abstain Broker Non-Votes Laurie B. Burns 95,060,944 17,727,239 137,819 14,178,570 Robert E. Cramer 71,387,274 41,349,899 188,829 14,178,570 Donna D. Fraiche 81,761,146 31,021,658 143,198 14,178,570 William A. Lamkin 94,808,514 17,932,956 184,532 14,178,570 Rajan C. Penkar 95,227,689 17,547,601 150,712 14,178,570 Christopher J. Bilotto 95,546,693 17,225,521 153,788 14,178,570 Adam Portnoy 74,500,382 38,258,808 166,812 14,178,570”

Sagimet Biosciences Inc. shareholders approved Ratification of Independent Registered Public Accountant at the 2026-06-12 meeting.

“Proposal 2 - Ratification of Independent Registered Public Accountant . The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year was ratified, as follows: For Against Abstentions Broker Non-Votes 19,091,619 13,960 35,224 0”

Sagimet Biosciences Inc. shareholders approved Election of Class III Directors at the 2026-06-12 meeting.

“Each of Jennifer Jarrett, Anne Phillips, M.D., David Happel and George Kemble, Ph.D. were elected to the Board to serve as Class III directors until the 2029 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation, retirement, disqualification or removal, as follows: Name For Withheld Broker Non-Votes Jennifer Jarrett 6,461,429 2,555,268 10,124,106 Anne Phillips, M.D. 7,806,504 1,210,193 10,124,106 David Happel 8,753,884 262,813 10,124,106 George Kemble, Ph.D. 8,688,684 328,013 10,124,106”

Repay Holdings Corp shareholders approved Ratification of the Audit Committee’s Appointment of Grant Thornton, LLP as the Independent Registered Public Accountant at the 2026-12-31 meeting.

“Proposal 4: Ratification of the Audit Committee’s Appointment of Grant Thornton, LLP as the Independent Registered Public Accountant. Shares Voted For Shares Voted Against Abstained 84,658,413 445,177 36,354 As a result, the Company’s stockholders ratified the selection of Grant Thornton, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

Repay Holdings Corp shareholders approved Approval of an Amendment and Restatement of the Omnibus Incentive Plan.

“Proposal 3: Approval of an Amendment and Restatement of the Omnibus Incentive Plan. Shares Voted For Shares Voted Against Abstained Broker Non-Votes 46,757,481 23,566,539 8,926,930 5,888,994 As a result, the Company’s stockholders approved the Third Amended and Restated Omnibus Incentive Plan.”

Repay Holdings Corp shareholders approved Advisory Vote on Executive Compensation.

“Proposal 2: Advisory Vote on Executive Compensation. Shares Voted For Shares Voted Against Abstained Broker Non-Votes 36,772,506 32,764,335 9,714,109 5,888,994 As a result, the Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.”

Repay Holdings Corp shareholders approved Election of Directors for Terms Expiring at the 2027 Annual Meeting of Stockholders.

“Proposal 1: Election of Directors for Terms Expiring at the 2027 Annual Meeting of Stockholders. Shares Voted For Shares Withheld Broker Non-Votes Paul R. Garcia 50,647,150 28,603,800 5,888,994 Maryann Goebel 50,731,863 28,519,087 5,888,994 Peter J. Kight 50,193,176 29,057,774 5,888,994 John Morris 50,732,737 28,518,213 5,888,994 Emnet Rios 50,747,059 28,503,891 5,888,994 Richard E. Thornburgh 50,195,764 29,055,186 5,888,994 As a result, each nominee was elected to serve as a director for a term expiring at the 2027 annual meeting of stockholders.”

ACM Research, Inc. shareholders approved Ratification of appointment of Ernst & Young Hua Ming LLP as independent auditor for fiscal year 2026 at the 2026-06-10 meeting.

“Proposal 2. Stockholders ratified the appointment of Ernst & Young Hua Ming LLP as our independent auditor for the fiscal year ending December 31, 2026 by the following vote: For Against Abstain Ratification of Appointment of Ernst & Young Hua Ming LLP for 2026 135,717,653 40,635 56,209”

ACM Research, Inc. shareholders approved Election of Directors at the 2026-06-10 meeting.

“Proposal 1. Stockholders voted as follows with respect to the election of each of the nominees for director identified in the proxy statement: Nominee For Withhold Broker Non-Votes David H. Wang 122,956,333 6,072,472 6,785,692 Haiping Dun 125,995,407 3,033,398 6,785,692 Tracy Liu 121,026,446 8,002,359 6,785,692 Charles Pappis 117,316,569 11,712,236 6,785,692”

Janux Therapeutics, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-11 meeting.

“Proposal 3: Advisory Vote on Executive Compensation The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of our named executive officers as disclosed in the Proxy Statement. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 42,749,182 4,574,376 46,341 6,375,023”

Janux Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-11 meeting.

“Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Votes For Votes Against Abstentions 53,560,969 113,446 70,507”

Janux Therapeutics, Inc. shareholders approved Election of Directors at the 2026-06-11 meeting.

“Proposal 1: Election of Directors The Company’s stockholders elected the two persons listed below as Class II directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows: Name of Director Elected Votes For Votes Withheld Broker Non-Votes Natasha Hernday 42,850,103 4,519,796 6,375,023 Eric Dobmeier 46,279,387 1,090,512 6,375,023”

Century Therapeutics, Inc. shareholders approved Approval of an adjournment of the Annual Meeting to the extent there were insufficient votes to approve Proposal 3 at the 2026-06-11 meeting.

“The adjournment of the Annual Meeting to the extent there were insufficient votes to approve Proposal 3 was approved, but such an adjournment was not necessary in light of the approval of Proposal 3 at the Annual Meeting. The adjournment was approved, as follows: For Against Abstentions Broker Non-Votes 117,181,181 18,419,826 88,087 0”

Century Therapeutics, Inc. shareholders approved Approval of an amendment to the Second Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 300,000,000 to 450,000,000 at the 2026-06-11 meeting.

“The amendment to the Company’s Second Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 300,000,000 to 450,000,000 was approved, as follows: For Against Abstentions Broker Non-Votes 117,444,445 18,150,386 94,262 0”

Century Therapeutics, Inc. shareholders approved Ratification of Independent Registered Public Accountant at the 2026-06-11 meeting.

“The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year was ratified, as follows: For Against Abstentions Broker Non-Votes 135,560,408 107,111 21,578 0”

Century Therapeutics, Inc. shareholders approved Election of Class II Directors at the 2026-06-11 meeting.

“Each of Alessandro Riva, M.D. and Han Lee, Ph.D., M.B.A., were elected to the Company’s Board to serve as Class II directors until the 2029 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation, retirement, disqualification or removal, as follows: Name For Withheld Broker Non-Votes Alessandro Riva, M.D. 96,165,182 17,582,584 21,941,333 Han Lee, Ph.D., M.B.A. 113,675,805 71,961 21,941,333”

Atara Biotherapeutics, Inc. shareholders approved Ratification of appointment of independent registered public accounting firm at the 2026-06-09 meeting.

“4. Ratification of appointment of independent registered public accounting firm For Against Abstentions 6,490,311 29,237 1,504 The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

Atara Biotherapeutics, Inc. shareholders approved Proposal to approve the first amendment to the Company’s 2024 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 400,000 at the 2026-06-09 meeting.

“3. Proposal to approve the first amendment to the Company’s 2024 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 400,000 For Against Abstain Broker Non-Votes 3,521,021 51,327 3,076 2,945,628 The stockholders approved the amendment to the Company’s 2024 Equity Incentive Plan, as disclosed in the Proxy Statement.”

Atara Biotherapeutics, Inc. shareholders approved Advisory vote to approve on the compensation of the Company's named executive officers at the 2026-06-09 meeting.

“2. Advisory vote to approve on the compensation of the Company’s named executive officers For Against Abstain Broker Non-Votes 3,526,411 44,481 4,532 2,945,628 The stockholders approved, on an advisory basis, the compensation awarded to the Company’s named executive officers, as disclosed in the Proxy Statement.”

Atara Biotherapeutics, Inc. shareholders approved Election of Directors at the 2026-06-09 meeting.

“1. Election of Directors Nominee For Withheld Broker Non-Votes AnhCo Nguyen Ph.D. 3,543,113 32,311 2,945,628 Nachi Subramanian 2,581,435 993,989 2,945,628 Each of the two nominees for director was elected to serve until the 2029 annual meeting of stockholders and until their respective successors are elected.”

CLOVER HEALTH INVESTMENTS, CORP. /DE shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-10 meeting.

“Proposal 3: Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the vote were as follows: FOR AGAINST ABSTAIN 1,188,467,663 2,471,606 1,391,903”

CLOVER HEALTH INVESTMENTS, CORP. /DE shareholders approved Non-binding advisory vote to approve the compensation of the Company's Named Executive Officers for 2025 at the 2026-06-10 meeting.

“Proposal 2: Non-binding advisory vote to approve the compensation of the Company's Named Executive Officers for 2025. The stockholders vote to approve, on a non-binding advisory basis, the compensation of the Company's Named Executive Officers for 2025. The results of the vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTE 1,003,065,402 9,811,825 1,663,812 177,790,033”

CLOVER HEALTH INVESTMENTS, CORP. /DE shareholders approved Election of Three Class II Directors at the 2026-06-10 meeting.

“Proposal 1: Election of Three Class II Directors. Demetrios L. Kouzoukas, Andrew Toy and Thomas L. Tran were each elected to the Company’s Board of Directors as Class II directors, to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified. The results of the election were as follows: FOR WITHHELD BROKER NON-VOTE Demetrios L. Kouzoukas 1,003,131,251 11,409,888 177,790,033 Andrew Toy 1,011,117,814 3,423,325 177,790,033 Thomas L. Tran 996,918,879 17,622,260 177,790,033”

GCM Grosvenor Inc. shareholders approved To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-09 meeting.

“Proposal Two. To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the voting were as follows: For Against Abstain Broker Non-Votes 224,093,615 289,113 28,932 0”

GCM Grosvenor Inc. shareholders approved To elect Michael J. Sacks, Angela Blanton, Francesca Cornelli, David A. Helfand, Jonathan R. Levin, Stephen Malkin and Samuel C. Scott III as directors at the 2026-06-09 meeting.

“Proposal One. To elect Michael J. Sacks, Angela Blanton, Francesca Cornelli, David A. Helfand, Jonathan R. Levin, Stephen Malkin and Samuel C. Scott III as directors to serve until the Annual Meeting of Stockholders to be held in 2027, and until their respective successors shall have been duly elected and qualified. The results of the voting were as follows: Nominee For Withheld Broker Non-Votes Michael J. Sacks 211,407,478 8,306,171 4,698,011 Angela Blanton 205,452,473 14,261,176 4,698,011 Francesca Cornelli 205,452,473 14,261,176 4,698,011 David A. Helfand 203,561,805 16,151,844 4,698,011 Jonathan R. Levin 212,994,595 6,719,054 4,698,011 Stephen Malkin 212,323,773 6,389,876 4,698,011 Samuel C. Scott III 200,341,959 19,371,690 4,698,011”

G III APPAREL GROUP LTD /DE/ shareholders approved Advisory Vote on Compensation of the Company’s Named Executive Officers at the 2026-06-11 meeting.

“Proposal No. 2: Advisory Vote on Compensation of the Company’s Named Executive Officers The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers as follows: ​ ​ ​ ​ Votes For Votes Against Abstentions Broker Non-Votes 28,785,238 5,897,634 54,264 1,394,854”

G III APPAREL GROUP LTD /DE/ shareholders approved Election of Directors at the 2026-06-11 meeting.

“Proposal No. 1: Election of Directors The Company’s stockholders elected each of the eleven nominees for director to serve until the next Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified based on the following votes: ​ ​ ​ ​ ​ Name Votes For Votes Withheld Broker Non-Votes Morris Goldfarb 33,911,381 825,755 1,394,854 Sammy Aaron 33,959,128 778,008 1,394,854 Thomas J. Brosig 32,021,253 2,715,883 1,394,854 Joyce F. Brown 34,093,539 643,597 1,394,854 Jeffrey Goldfarb 34,154,345 582,791 1,394,854 Victor Herrero 26,219,740 8,517,396 1,394,854 Patti H. Ongman 34,334,651 402,485 1,394,854 Michael Shaffer 31,639,230 3,097,906 1,394,854 Cheryl Vitali 33,665,334 1,071,802 1,394,854 Richard White 29,730,748 5,006,388 1,394,854 Andrew Yaeger 31,737,604 2,999,532 1,394,854”

PULSE BIOSCIENCES, INC. shareholders approved Ratification of appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-11 meeting.

“2. Ratification of Appointment of Independent Registered Public Accounting Firm For Against Abstained Broker Non-votes 45,976,355 8,265 17,074 N/A The stockholders ratified the appointment of Deloitte & Touche LLP”

PULSE BIOSCIENCES, INC. shareholders approved Election of seven directors to hold office until the Company’s 2027 annual meeting and until their successors are duly elected and qualified at the 2026-06-11 meeting.

“1. Election of Directors Nominee For Against Abstained Broker Non-votes Robert W. Duggan 33,443,582 1,583,174 388 10,974,550 Paul A. LaViolette 34,264,295 759,401 3,448 10,974,550 Maria Sainz 35,007,101 18,349 1,694 10,974,550 Manmeet S. Soni 33,560,875 1,464,574 1,695 10,974,550 Darrin R. Uecker 34,246,413 779,036 1,695 10,974,550 Richard A. van den Broek 34,278,978 746,471 1,695 10,974,550 Mahkam Zanganeh, D.D.S. 34,241,938 783,511 1,695 10,974,550 Each director nominee was duly elected”

Athena Technology Acquisition Corp. II shareholders approved Approval to amend the Charter to extend the date by which the Company must consummate a business combination from June 14, 2026 to up to March 14, 2027, subject to certain requirements. at the 2026-06-11 meeting.

“Proposal 1 — Approval to amend the Charter to extend the date by which the Company must consummate a business combination from June 14, 2026 to up to March 14, 2027, subject to certain requirements. Votes For Votes Against Votes Abstained Broker Non-Votes 9,835,330 0 0 0 Based on the foregoing votes, the stockholders approved the Amendment to the Charter.”

Q2 Holdings, Inc. shareholders approved Advisory vote to approve the compensation of the Company's named executive officers. at the 2026-06-10 meeting.

“Proposal 3: Advisory vote to approve the compensation of the Company's named executive officers. For Against Abstaining Broker Non-votes 52,396,434 1,518,928 24,202 3,970,325 Based on the votes set forth above, the stockholders approved on an advisory basis the compensation of the Company's named executive officers.”

Q2 Holdings, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-10 meeting.

“Proposal 2: Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. For Against Abstaining 57,526,616 354,049 29,224 Based on the votes set forth above, the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified.”

Q2 Holdings, Inc. shareholders approved Election of Directors to hold office for one-year terms or until their respective successors are elected and qualified, or their earlier death, resignation or removal. at the 2026-06-10 meeting.

“Proposal 1: Election of Directors to hold office for one-year terms or until their respective successors are elected and qualified, or their earlier death, resignation or removal. For Withheld Broker Non-votes R. Lynn Atchison 53,797,230 142,334 3,970,325 Matthew P. Flake 53,218,242 721,322 3,970,325 Stephen C. Hooley 52,994,546 945,018 3,970,325 Andre L. Mintz 53,823,194 116,370 3,970,325 James R. Offerdahl 52,869,978 1,069,586 3,970,325 Margaret L. Taylor 53,053,545 886,019 3,970,325 Lynn Antipas Tyson 53,363,575 575,989 3,970,325 Based on the votes set forth above, all of the director nominees were duly elected.”

Immunome Inc. shareholders approved Advisory Vote on the Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation at the 2026-06-09 meeting.

“The Company’s stockholders indicated, on an advisory basis, their preference for the frequency of stockholder advisory votes on the compensation of the Company’s named executive officers. The final voting results are as follows: 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 91,949,591 368,407 41,534 22,034 11,768,578”

Immunome Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-09 meeting.

“The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as described in the Proxy Statement. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 90,908,436 1,442,116 31,014 11,768,578”

Immunome Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-09 meeting.

“The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 by the Audit Committee of the Company’s Board of Directors. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 104,100,900 27,134 22,110 -”

Immunome Inc. shareholders approved Election of Directors at the 2026-06-09 meeting.

“The Company’s stockholders elected the three persons listed below as Class III directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes James Boylan 70,209,570 22,171,996 11,768,578 Sandra Swain, M.D. 92,157,301 224,265 11,768,578 Philip Wagenheim 92,162,632 218,934 11,768,578”

Nuvectis Pharma, Inc. shareholders approved Ratification of Kesselman & Kesselman as independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-11 meeting.

“The vote with respect to the ratification of Kesselman & Kesselman as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, was as follows: Votes For Votes Against Abstentions / Votes Withheld Broker Non-Votes 15,662,222 10,574 520,890 -”

Nuvectis Pharma, Inc. shareholders approved Election of Class I director to hold office until the 2029 annual meeting at the 2026-06-11 meeting.

“The vote with respect to the election of the Class I director to hold office until the 2029 annual meeting was as follows: Director Votes For Votes Against Abstentions / Votes Withheld Broker Non-Votes Ron Bentsur 8,354,838 391,265 216 7,447,367”

Senmiao Technology Ltd shareholders approved Approval of Issuance of Shares of Common Stock and Warrants in Connection with Private Placement at the 2026-06-11 meeting.

“Proposal 6 : The Company’s stockholders voted to approve the issuance of shares of Common Stock and warrants to purchase shares of Common Stock (the “PIPE Warrants”) in connection with the Company’s private placement of up to $11,000,000 pursuant to the Securities Purchase Agreement dated April 23, 2026 (the “PIPE Proposal”) by the following vote: For Against Abstentions Broker Non-Votes 2,331,324 28,248 1,493 818,056”

Senmiao Technology Ltd shareholders approved Approval of Amendment to Articles of Incorporation to Increase Authorized Shares at the 2026-06-11 meeting.

“Proposal 5 : The Company’s stockholders voted to approve an amendment to the Company’s Articles of Incorporation to increase the total number of authorized shares of Common Stock from 50,000,000 to 500,000,000 (“Authorized Share Increase Proposal”) by the following vote: For Against Abstentions 2,747,548 383,827 47,746”

Senmiao Technology Ltd shareholders approved Authorization of Reverse Stock Split at the 2026-06-11 meeting.

“Proposal 4 : The Company’s stockholders voted to authorize (but not require) the Board of Directors to effect one or more reverse stock splits of the Company’s issued and outstanding Common Stock at any time prior to the Company’s next annual meeting of stockholders, with an aggregate ratio of up to one-for-one hundred (1:100), with the exact timing and ratio to be determined by the Board of Directors in its sole discretion (“Reverse Stock Split Proposal”) by the following vote: For Against Abstentions 2,794,305 384,729 87”

Senmiao Technology Ltd shareholders approved Approval of Issuance of Shares of Common Stock Underlying Warrants at the 2026-06-11 meeting.

“Proposal 3 : The Company’s stockholders voted to approve, for purposes of Nasdaq Listing Rule 5635, the issuance of shares of Common Stock underlying the warrants issued pursuant to the Securities Purchase Agreement dated November 14, 2025 (“Warrant Share Issuance Proposal”) by the following vote: For Against Abstentions Broker Non-Votes 2,334,904 26,127 34 818,057”

Senmiao Technology Ltd shareholders approved Ratification of Appointment of Marcum Asia CPAs LLP as Independent Registered Public Accounting Firm at the 2026-06-11 meeting.

“Proposal 2 : The Company’s stockholders voted to ratify appointment of Marcum Asia CPAs LLP as the Company’s registered public accounting firm for the fiscal year ending March 31, 2026 by the following vote: For Against Abstentions 3,150,280 28,202 639”